A solid point -- though the therapy is interesting on a novelty scale, the funding is decidedly vanilla. Grants fund the early research, patents are filed for n

A solid point -- though the therapy is interesting on a novelty scale, the funding is decidedly vanilla. Grants fund the early research, patents are filed for novel findings, and if the therapy holds up eventually a large pharmaceutical firm will be necessary to perform the large scale trials. Slightly tangential, but I wonder where the IP in this discovery is? If there is nothing to sell but injecting cancer patients with standard lab-grade measles, I think it is particularly open to being copied. Granted the measles used is genetically tweaked, but nothing I believe to enhance the therapeutic effectiveness.